Annual CFF
-$1.27 M
-$2.49 M-204.11%
December 31, 2023
Summary
- As of February 7, 2025, ALDX annual cash flow from financing activities is -$1.27 million, with the most recent change of -$2.49 million (-204.11%) on December 31, 2023.
- During the last 3 years, ALDX annual CFF has fallen by -$43.17 million (-103.03%).
- ALDX annual CFF is now -100.65% below its all-time high of $194.50 million, reached on December 31, 2021.
Performance
ALDX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$197.40 K
-$197.40 K-100.00%
September 30, 2024
Summary
- As of February 7, 2025, ALDX quarterly cash flow from financing activities is -$197.40 thousand, with the most recent change of -$197.40 thousand (-100.00%) on September 30, 2024.
- Over the past year, ALDX quarterly CFF has increased by +$118.40 thousand (+37.49%).
- ALDX quarterly CFF is now -100.16% below its all-time high of $120.37 million, reached on June 30, 2021.
Performance
ALDX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$1.19 M
+$118.40 K+9.04%
September 30, 2024
Summary
- As of February 7, 2025, ALDX TTM cash flow from financing activities is -$1.19 million, with the most recent change of +$118.40 thousand (+9.04%) on September 30, 2024.
- Over the past year, ALDX TTM CFF has dropped by -$933.60 thousand (-362.00%).
- ALDX TTM CFF is now -100.54% below its all-time high of $220.66 million, reached on June 30, 2021.
Performance
ALDX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ALDX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -204.1% | +37.5% | -362.0% |
| 3 y3 years | -103.0% | -409.4% | -100.6% |
| 5 y5 years | -101.6% | -101.3% | -105.0% |
ALDX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -100.7% | at low | -116.5% | +80.5% | -100.6% | +9.0% |
| 5 y | 5-year | -100.7% | at low | -100.2% | +80.5% | -100.5% | +9.0% |
| alltime | all time | -100.7% | at low | -100.2% | +80.5% | -100.5% | +9.0% |
Aldeyra Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$197.40 K(<-9900.0%) | -$1.19 M(-9.0%) |
| Jun 2024 | - | $0.00(-100.0%) | -$1.31 M(+0.4%) |
| Mar 2024 | - | $18.20 K(-101.8%) | -$1.30 M(+2.7%) |
| Dec 2023 | -$1.27 M(-204.1%) | -$1.01 M(+220.6%) | -$1.27 M(+392.5%) |
| Sep 2023 | - | -$315.80 K(-6058.5%) | -$257.90 K(-120.6%) |
| Jun 2023 | - | $5300.00(-89.9%) | $1.25 M(+0.4%) |
| Mar 2023 | - | $52.60 K(>+9900.0%) | $1.25 M(+2.4%) |
| Dec 2022 | $1.22 M(-99.4%) | $0.00(-100.0%) | $1.22 M(0.0%) |
| Sep 2022 | - | $1.20 M(>+9900.0%) | $1.22 M(+1300.8%) |
| Jun 2022 | - | $0.00(-100.0%) | $87.10 K(-99.9%) |
| Mar 2022 | - | $23.30 K(>+9900.0%) | $120.46 M(-38.1%) |
| Dec 2021 | $194.50 M(+364.2%) | $0.00(-100.0%) | $194.50 M(0.0%) |
| Sep 2021 | - | $63.80 K(-99.9%) | $194.50 M(-11.9%) |
| Jun 2021 | - | $120.37 M(+62.5%) | $220.66 M(+95.8%) |
| Mar 2021 | - | $74.06 M(>+9900.0%) | $112.71 M(+169.0%) |
| Dec 2020 | $41.90 M(+77.7%) | $0.00(-100.0%) | $41.90 M(-16.6%) |
| Sep 2020 | - | $26.22 M(+111.1%) | $50.24 M(+29.3%) |
| Jun 2020 | - | $12.42 M(+282.0%) | $38.86 M(+47.1%) |
| Mar 2020 | - | $3.25 M(-61.0%) | $26.42 M(+12.1%) |
| Dec 2019 | $23.58 M(-70.7%) | $8.33 M(-43.9%) | $23.58 M(-71.1%) |
| Sep 2019 | - | $14.84 M(<-9900.0%) | $81.53 M(+20.3%) |
| Jun 2019 | - | -$9100.00(-102.2%) | $67.80 M(-11.8%) |
| Mar 2019 | - | $407.60 K(-99.4%) | $76.84 M(-4.6%) |
| Dec 2018 | $80.53 M | $66.29 M(+5855.9%) | $80.53 M(+463.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $1.11 M(-87.7%) | $14.29 M(-64.3%) |
| Jun 2018 | - | $9.03 M(+120.6%) | $40.00 M(+29.3%) |
| Mar 2018 | - | $4.09 M(+8427.7%) | $30.94 M(-17.3%) |
| Dec 2017 | $37.43 M(+193.8%) | $48.00 K(-99.8%) | $37.43 M(+0.0%) |
| Sep 2017 | - | $26.83 M(<-9900.0%) | $37.42 M(+256.8%) |
| Jun 2017 | - | -$29.70 K(-100.3%) | $10.49 M(-55.1%) |
| Mar 2017 | - | $10.58 M(>+9900.0%) | $23.33 M(+83.2%) |
| Dec 2016 | $12.74 M(-55.3%) | $36.10 K(-135.4%) | $12.74 M(+0.4%) |
| Sep 2016 | - | -$102.10 K(-100.8%) | $12.69 M(-0.5%) |
| Jun 2016 | - | $12.81 M(<-9900.0%) | $12.75 M(-34.3%) |
| Mar 2016 | - | -$9700.00(-31.7%) | $19.42 M(-31.8%) |
| Dec 2015 | $28.47 M(+183.1%) | -$14.20 K(-60.8%) | $28.47 M(-0.0%) |
| Sep 2015 | - | -$36.20 K(-100.2%) | $28.48 M(+0.5%) |
| Jun 2015 | - | $19.48 M(+115.5%) | $28.34 M(+48.0%) |
| Mar 2015 | - | $9.04 M(>+9900.0%) | $19.15 M(+90.4%) |
| Dec 2014 | $10.05 M(+168.5%) | $0.00(-100.0%) | $10.05 M(-9.9%) |
| Sep 2014 | - | -$176.80 K(-101.7%) | $11.15 M(-15.9%) |
| Jun 2014 | - | $10.28 M(<-9900.0%) | $13.27 M(+351.0%) |
| Mar 2014 | - | -$52.80 K(-104.8%) | $2.94 M(-21.4%) |
| Dec 2013 | $3.75 M(+113.9%) | $1.10 M(-43.3%) | $3.75 M(+41.5%) |
| Sep 2013 | - | $1.94 M(-4746.3%) | $2.65 M(+273.4%) |
| Jun 2013 | - | -$41.70 K(-105.6%) | $708.70 K(-5.6%) |
| Mar 2013 | - | $750.40 K | $750.40 K |
| Dec 2012 | $1.75 M(>+9900.0%) | - | - |
| Dec 2011 | $0.00 | - | - |
FAQ
- What is Aldeyra Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics annual CFF year-on-year change?
- What is Aldeyra Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics quarterly CFF year-on-year change?
- What is Aldeyra Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics TTM CFF year-on-year change?
What is Aldeyra Therapeutics annual cash flow from financing activities?
The current annual CFF of ALDX is -$1.27 M
What is the all time high annual CFF for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high annual cash flow from financing activities is $194.50 M
What is Aldeyra Therapeutics annual CFF year-on-year change?
Over the past year, ALDX annual cash flow from financing activities has changed by -$2.49 M (-204.11%)
What is Aldeyra Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ALDX is -$197.40 K
What is the all time high quarterly CFF for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high quarterly cash flow from financing activities is $120.37 M
What is Aldeyra Therapeutics quarterly CFF year-on-year change?
Over the past year, ALDX quarterly cash flow from financing activities has changed by +$118.40 K (+37.49%)
What is Aldeyra Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ALDX is -$1.19 M
What is the all time high TTM CFF for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high TTM cash flow from financing activities is $220.66 M
What is Aldeyra Therapeutics TTM CFF year-on-year change?
Over the past year, ALDX TTM cash flow from financing activities has changed by -$933.60 K (-362.00%)